Pfizer Operating Income 2010-2022 | PFE

Pfizer annual/quarterly operating income history and growth rate from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Pfizer operating income for the quarter ending September 30, 2022 was $8.943B, a 45.49% increase year-over-year.
  • Pfizer operating income for the twelve months ending September 30, 2022 was $33.554B, a 95.71% increase year-over-year.
  • Pfizer annual operating income for 2021 was $19.433B, a 135.55% increase from 2020.
  • Pfizer annual operating income for 2020 was $8.25B, a 22.95% increase from 2019.
  • Pfizer annual operating income for 2019 was $6.71B, a 18.3% increase from 2018.
Pfizer Annual Operating Income
(Millions of US $)
2021 $19,433
2020 $8,250
2019 $6,710
2018 $5,672
2017 $13,722
2016 $12,145
2015 $11,824
2014 $13,249
2013 $15,184
2012 $15,264
2011 $13,967
2010 $13,412
2009 $10,959
Pfizer Quarterly Operating Income
(Millions of US $)
2022-09-30 $8,943
2022-06-30 $12,219
2022-03-31 $9,401
2021-12-31 $2,991
2021-09-30 $6,147
2021-06-30 $5,606
2021-03-31 $4,689
2020-12-31 $703
2020-09-30 $2,448
2020-06-30 $2,072
2020-03-31 $3,027
2019-12-31 $-4,928
2019-09-30 $2,958
2019-06-30 $4,266
2019-03-31 $4,414
2018-12-31 $-6,017
2018-09-30 $3,764
2018-06-30 $3,976
2018-03-31 $3,949
2017-12-31 $2,307
2017-09-30 $3,664
2017-06-30 $3,741
2017-03-31 $4,010
2016-12-31 $1,756
2016-09-30 $3,021
2016-06-30 $3,477
2016-03-31 $3,891
2015-12-31 $1,834
2015-09-30 $3,358
2015-06-30 $3,595
2015-03-31 $3,037
2014-12-31 $2,147
2014-09-30 $3,682
2014-06-30 $3,950
2014-03-31 $3,470
2013-12-31 $3,043
2013-09-30 $3,984
2013-06-30 $4,287
2013-03-31 $3,870
2012-12-31 $2,560
2012-09-30 $3,743
2012-06-30 $4,868
2012-03-31 $4,093
2011-12-31 $1,913
2011-09-30 $4,088
2011-06-30 $4,021
2011-03-31 $3,945
2010-12-31 $1,887
2010-09-30 $3,763
2010-06-30 $4,201
2010-03-31 $3,561
2009-12-31 $-39
2009-09-30 $4,131
2009-06-30 $3,121
2009-03-31 $3,746
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $285.774B $81.288B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $467.679B 18.00
Eli Lilly (LLY) United States $356.089B 44.94
AbbVie (ABBV) United States $289.429B 12.00
Novo Nordisk (NVO) Denmark $287.171B 37.66
Merck (MRK) United States $278.995B 14.37
Novartis AG (NVS) Switzerland $199.112B 15.00